{"id":400005,"date":"2020-12-15T09:04:08","date_gmt":"2020-12-15T14:04:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400005"},"modified":"2020-12-15T09:04:08","modified_gmt":"2020-12-15T14:04:08","slug":"adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/","title":{"rendered":"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Dec. 15, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0M.S.Q. Ventures (&#8220;MSQ&#8221;) is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT\u00a0BioPharma\u00a0(CY) Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg\" title=\"MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. From understanding key segments of the China healthcare market to identifying and vetting the high potential counterparties to negotiating deals aimed at maximizing value creation, our team focuses on results, prioritizes efficiency to guide our clients through the entire process.\" alt=\"MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. From understanding key segments of the China healthcare market to identifying and vetting the high potential counterparties to negotiating deals aimed at maximizing value creation, our team focuses on results, prioritizes efficiency to guide our clients through the entire process.\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Under the terms of the agreement, ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">Singapore<\/span> to Overland ADCT Biopharma, in which Overland Pharmaceuticals has invested <span class=\"xn-money\">$50 million<\/span>. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics a 49% stake.\u00a0ADC Therapeutics can also earn milestone payments and royalties from the license agreement with Overland ADCT BioPharma.\u00a0<\/p>\n<p>&#8220;As we prepare for the potential U.S. launch of\u00a0Lonca\u00a0in 2021, we are delighted that Overland ADCT BioPharma will expand access to the therapy, as well as three of our other\u00a0pyrrolobenzodiazepine (PBD)-based antibody drug conjugates, to address patient needs in greater <span class=\"xn-location\">China<\/span>,&#8221;\u00a0said <span class=\"xn-person\">Chris Martin<\/span>, CEO of ADC Therapeutics. &#8220;The MSQ team has been working\u00a0from A to Z to help us understand <span class=\"xn-location\">China&#8217;s<\/span>\u00a0market, develop a plan, execute strategic objectives, and advise\u00a0on\u00a0this\u00a0transaction.\u00a0Their systematic approach and laser focus on results contributed\u00a0to\u00a0our success.&#8221;<\/p>\n<p>\n        <span class=\"xn-person\">Ed Zhang<\/span>, Co-founders\u00a0of Overland Pharmaceuticals, stated, &#8220;We are excited to bring these first four candidates into Overland ADCT BioPharma&#8217;s\u00a0portfolio and look forward to developing this new company into a leading oncology player in <span class=\"xn-location\">China<\/span>. We are pleased to work with ADC Therapeutics, a pioneer in the field of ADCs, on this strategic venture. MSQ&#8217;s professionalism and understanding of both parties&#8217; objectives helped to expedite this successful transaction especially during COVID-19.&#8221; <\/p>\n<p>As ADC Therapeutics embarks on this exciting phase of its global plan, <span class=\"xn-person\">Echo Hindle-Yang<\/span>, CEO of MSQ reflected on the transaction, &#8220;This new cross-border venture is another example that even in the era of COVID-19, global innovators such as ADC Therapeutics and Overland Pharmaceuticals have joined forces. We are heartened by what this could mean for cancer patients.\u00a0\u00a0We congratulate both teams and look forward to more breakthroughs from them in the future.&#8221;<\/p>\n<p>About MSQ\u00a0\u00a0<br \/>M.S.Q. Ventures is a <span class=\"xn-location\">New York<\/span>-based\u00a0<b>cross-border advisory<\/b>\u00a0firm that bridges the\u00a0<b>healthcare\u00a0<\/b>industries globally by offering our deep knowledge, strong network, and local insights into the\u00a0<b>China\u00a0<\/b>market.\u00a0\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Echo Hindle-Yang<\/span>, CEO, MSQ<br \/><a target=\"_blank\" href=\"mailto:hindleyang@msqventures.com\" rel=\"nofollow noopener noreferrer\">hindleyang@msqventures.com<\/a><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY23749&amp;sd=2020-12-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures-301192815.html\">http:\/\/www.prnewswire.com\/news-releases\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures-301192815.html<\/a><\/p>\n<p>SOURCE  MSQ Ventures<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY23749&amp;Transmission_Id=202012150900PR_NEWS_USPR_____NY23749&amp;DateId=20201215\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212;\u00a0M.S.Q. Ventures (&#8220;MSQ&#8221;) is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT\u00a0BioPharma\u00a0(CY) Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.\u00a0 Under the terms of the agreement, ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT Biopharma, in which Overland Pharmaceuticals has invested $50 million. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics a 49% stake.\u00a0ADC Therapeutics can also earn milestone payments and royalties from the license agreement with Overland ADCT BioPharma.\u00a0 &#8220;As we prepare for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400005","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212;\u00a0M.S.Q. Ventures (&#8220;MSQ&#8221;) is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT\u00a0BioPharma\u00a0(CY) Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.\u00a0 Under the terms of the agreement, ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT Biopharma, in which Overland Pharmaceuticals has invested $50 million. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics a 49% stake.\u00a0ADC Therapeutics can also earn milestone payments and royalties from the license agreement with Overland ADCT BioPharma.\u00a0 &#8220;As we prepare for &hellip; Continue reading &quot;ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T14:04:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures\",\"datePublished\":\"2020-12-15T14:04:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/\"},\"wordCount\":433,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1385527\\\/MSQ_Ventures_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/\",\"name\":\"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1385527\\\/MSQ_Ventures_Logo.jpg\",\"datePublished\":\"2020-12-15T14:04:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1385527\\\/MSQ_Ventures_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1385527\\\/MSQ_Ventures_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/","og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures - Market Newsdesk","og_description":"PR Newswire NEW YORK, Dec. 15, 2020 \/PRNewswire\/ &#8212;\u00a0M.S.Q. Ventures (&#8220;MSQ&#8221;) is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT\u00a0BioPharma\u00a0(CY) Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.\u00a0 Under the terms of the agreement, ADC Therapeutics licensed exclusive development and commercialization rights to Lonca, ADCT-602, ADCT-601 and ADCT-901 for greater China and Singapore to Overland ADCT Biopharma, in which Overland Pharmaceuticals has invested $50 million. Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics a 49% stake.\u00a0ADC Therapeutics can also earn milestone payments and royalties from the license agreement with Overland ADCT BioPharma.\u00a0 &#8220;As we prepare for &hellip; Continue reading \"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T14:04:08+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures","datePublished":"2020-12-15T14:04:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/"},"wordCount":433,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/","name":"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg","datePublished":"2020-12-15T14:04:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1385527\/MSQ_Ventures_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-and-overland-pharma-form-strategic-jv-to-expand-adc-drugs-development-and-commercialization-in-greater-china-and-singapore-advised-by-msq-ventures\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400005"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400005\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}